765090
Polyethylenimine, linear
average Mn 10,000, PDI ≤1.3
Synonym(s):
PEI
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
form
solid
mol wt
average Mn 10,000
mp
48-53 °C
PDI
≤1.3
storage temp.
2-8°C
InChI
1S/C2H5N/c1-2-3-1/h3H,1-2H2
InChI key
NOWKCMXCCJGMRR-UHFFFAOYSA-N
Looking for similar products? Visit Product Comparison Guide
General description
Polyethylenimine (linear) is a versatile cationic polymer with a high transfection efficiency. It is used as a gene delivery reagent. It is a non-lipid polycation that can be used to transfect oligonucleotides and plasmid into cells in vitro and in vivo.
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
A comparison of linear and branched polyethylenimine (PEI) with DCChol/DOPE liposomes for gene delivery to epithelial cells in vitro and in vivo
Gene Therapy, 10(19), 1654-1654 (2003)
Systemic linear polyethylenimine (L-PEI)-mediated gene delivery in the mouse
The journal of gene medicine, 2(2), 128-134 (2000)
Bromodomain and extra-terminal (BET) protein inhibitors suppress chondrocyte differentiation and restrain bone growth
The Journal of biological chemistry, 291(52), 26647-26657 (2016)
Pharmaceutical research, 25(12), 2972-2982 (2008-08-19)
The success of nucleic acid therapies depends upon delivery vehicle's ability to selectively and efficiently deliver therapeutic nucleic acids to target organ with minimal toxicity. The cationic polymer polyethylenimine (PEI) has been widely used for nucleic acid delivery due to
Biomaterials, 171, 34-45 (2018-04-22)
Limitation of current anti-Vascular Endothelial Growth Factor (VEGF) cancer therapy is transitory responses, inevitable relapses and its insufficient tumor-targeting. Thus, multifaceted approaches, including the development of bispecific antibodies and combination strategies targeting different pathways have been proposed as an alternative.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service